These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19362552)

  • 1. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.
    Reimer C; Søndergaard B; Hilsted L; Bytzer P
    Gastroenterology; 2009 Jul; 137(1):80-7, 87.e1. PubMed ID: 19362552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat.
    McColl KE; Gillen D
    Gastroenterology; 2009 Jul; 137(1):20-2. PubMed ID: 19482105
    [No Abstract]   [Full Text] [Related]  

  • 3. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial.
    Vaezi MF; Fass R; Vakil N; Reasner DS; Mittleman RS; Hall M; Shao JZ; Chen Y; Lane L; Gates AM; Currie MG
    Gastroenterology; 2020 Jun; 158(8):2093-2103. PubMed ID: 32092310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study.
    Zeng J; Zuo XL; Li YQ; Wei W; Lv GP
    Eur J Clin Pharmacol; 2007 Jun; 63(6):529-36. PubMed ID: 17468863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment-Are PPIs Addictive?
    Namikawa K; Björnsson ES
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial.
    Niklasson A; Lindström L; Simrén M; Lindberg G; Björnsson E
    Am J Gastroenterol; 2010 Jul; 105(7):1531-7. PubMed ID: 20332770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test.
    Armstrong D; Veldhuyzen SJ; Chung SA; Shapiro CM; Dhillon S; Escobedo S; Chakraborty BK; Mann V; Tanser L; Nevin K
    Can J Gastroenterol; 2005 Jun; 19(6):350-8. PubMed ID: 15997268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment.
    Lødrup AB; Reimer C; Bytzer P
    Scand J Gastroenterol; 2013 May; 48(5):515-22. PubMed ID: 23311977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Placebo-Controlled
    Sierra-Arango F; Castaño DM; Forero JD; Pérez-Riveros ED; Ardila Duarte G; Botero ML; Cárdenas A; De la Hoz-Valle J
    Can J Gastroenterol Hepatol; 2019; 2019():3926051. PubMed ID: 31929980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
    Vakil NB; Shaker R; Johnson DA; Kovacs T; Baerg RD; Hwang C; D'Amico D; Hamelin B
    Aliment Pharmacol Ther; 2001 Jul; 15(7):927-35. PubMed ID: 11421866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment.
    Miner PB; Johnson DA; Katz PO; Li J; Gatoulis SC; Pollack C
    Adv Ther; 2018 Nov; 35(11):2024-2040. PubMed ID: 30255418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
    Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
    J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptom profile in partial responders to a proton pump inhibitor compared with treatment-naïve patients with gastroesophageal reflux disease: a post hoc analysis of two study populations.
    Vakil N; Niklasson A; Denison H; Rydén A
    BMC Gastroenterol; 2014 Oct; 14():177. PubMed ID: 25304129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study.
    Cho JH; Koo JY; Kim KO; Lee SH; Jang BI; Kim TN
    Medicine (Baltimore); 2018 Oct; 97(43):e12732. PubMed ID: 30412065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?
    Farup PG; Juul-Hansen PH; Rydning A
    J Clin Gastroenterol; 2001 Sep; 33(3):206-9. PubMed ID: 11500608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
    Vakil NB; Huff FJ; Bian A; Jones DS; Stamler D
    Am J Gastroenterol; 2011 Aug; 106(8):1427-38. PubMed ID: 21519360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life.
    Takeshima F; Hashiguchi K; Onitsuka Y; Tanigawa K; Minami H; Matsushima K; Akazawa Y; Shiozawa K; Yamaguchi N; Taura N; Ohnita K; Ichikawa T; Isomoto H; Nakao K
    Med Sci Monit; 2015 Dec; 21():4111-21. PubMed ID: 26719012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.
    Tominaga K; Kato M; Takeda H; Shimoyama Y; Umegaki E; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Kusano M; Fujimoto K; Arakawa T;
    J Gastroenterol; 2014 Oct; 49(10):1392-405. PubMed ID: 24535455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised trial of the effect of a gastrin/CCK
    Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
    Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Clinical Predictors of Resolution of Sleep Disturbance Related to Frequent Nighttime Heartburn and Acid Regurgitation Symptoms in Individuals Taking Esomeprazole 20 mg or Placebo.
    Johnson DA; Le Moigne A; Li J; Pollack C; Nagy P
    Clin Drug Investig; 2016 Jul; 36(7):531-8. PubMed ID: 27074935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.